Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Lipid-Modified Oligonucleotides For Sample Barcoding in Droplet Microfluidics-Based Single-Cell RNA Sequencing

A new strategy for barcoding single living cells using lipid-modified oligonucleotides that can vastly enhance sample multiplexing in droplet microfluidics-based RNA sequencing

Small Molecule Pendrin Inhibitors for Treatment of Inflammatory Airway Diseases and Diuretic Resistance

Small molecule pendrin inhibitors for treating inflammatory lung diseases.

Novel Small Molecule Drug for the Treatment of Constipation and Oxalate Kidney Stones

UCSF researchers have developed a novel small molecule drug that specifically targets and inhibits SLC26A3 (DRA), an anion exchanger whose inhibition is expected to have therapeutic benefit in constipation and oxalate kidney stone disease.

“EchoCV”: A Web-Based Fully Automated Echocardiogram Interpretation System

Echo-CV is a novel, fully-automated system for analyzing images obtained from an echocardiogram that can be deployed on the web.

Chimeric Antigen Receptors For Phagocytosis (Car-P)

UCSF researchers have engineered a chimeric antigen receptor for phagocytosis (CAR-P) that promotes engulfment of cancer cells.

T Cell Signature Predictive of Clinical Outcome with Immunomodulatory Treatment

Biomarkers to predict responsiveness to anti-CTLA-4 antibodies

Novel Tumor-targeting Virus for Cancer Therapy

UCSF researchers have developed a novel engineered virus that specifically targets tumor cells using a knottin moiety, to effectively eliminate a number of cancer types.

NOVEL TUMOR SELECTIVE INTERNALIZING ANTIBODIES

Novel human monoclonal antibodies recognize a cell surface antigen that has limited normal tissue expression but is highly overexpressed in several types of cancers, including mesothelioma, melanoma, head and neck cancer, lung cancer, glioblastoma multiforme, pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, cervical cancer, skin cancer and testicular cancer. The antibodies can block tumor invasion, self-renewal and have potential to modulate immune effector cell function.